The ICC assay results indicated that the expression of erythroid differentiation-related proteins, including HIF-1α, EPO, c-Myc, GATA-1, and GATA-2, was increased in cancer cells treated with ATO (Figure 2E). The gene discussed is GATA2; the disease is cancer.